Form 8-K - Current report:
SEC Accession No. 0001516551-24-000108
Filing Date
2024-11-07
Accepted
2024-11-07 16:03:46
Documents
16
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K skye-20241107.htm   iXBRL 8-K 30247
2 EX-99.1 a241107_skyexq324financial.htm EX-99.1 106914
7 GRAPHIC skye-biosciencexdarkblue.jpg GRAPHIC 53384
  Complete submission text file 0001516551-24-000108.txt   345763

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT skye-20241107.xsd EX-101.SCH 2058
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT skye-20241107_def.xml EX-101.DEF 2386
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT skye-20241107_lab.xml EX-101.LAB 21921
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT skye-20241107_pre.xml EX-101.PRE 12620
18 EXTRACTED XBRL INSTANCE DOCUMENT skye-20241107_htm.xml XML 2537
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Filer) CIK: 0001516551 (see all company filings)

EIN.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42009 | Film No.: 241435455
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)